A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Bevacizumab (Primary) ; Everolimus (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 01 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
- 01 Aug 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
- 10 Feb 2018 Results (n=39) presented at the 2018 Genitourinary Cancers Symposium.